IP Library Granted Patent US 10,646,538
Granted Patent B2
US 10,646,538 · App. 15/517,839 · Granted May 12, 2020

Self-assembling tripeptides

Inventors: Rein Ulijn (Glasgow, GB); Tell Tuttle (Glasgow, GB); Pim Frederix (Glasgow, GB); Gary Scott (Glasgow, GB); Yousef Abul-Haija (Glasgow, GB)
Assignee: ENDO Biologics, Inc.
A61K38/06A61K9/0014A61L15/60B82Y40/00C07K5/0812C07K5/0815G16B15/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,646,538
App. No.
15/517,839
Granted
May 12, 2020
Kind
B2
Abstract

The present invention relates to a method of predicting the propensity of tripeptides to from aggregates in solution. The present invention also provides tripeptides which are able to form aggregates in solution, as well as uses thereof. The present invention also provides nanostructures formed by self-aggregation of tripeptides of the present invention. The present invention also provides pH responsive aggregates as well as methods of screening for the ability of a tripeptide to form a pH dependent aggregate or gel.

Claims (9)

1. A hydrogel comprising a self-aggregated tripeptide, wherein the self-aggregated tripeptide is selected from the group consisting of KFF, KFY, KFW, FYF, KYY, KYW, KWF, KWY, and KWW.

2. The hydrogel according to claim 1 , wherein the hydrogel further comprises an additional self-aggregated tripeptide selected from the group consisting of KFF, KFY, KFW, FYF, KYY, KYW, KWF, KWY, and KWW.

3. The hydrogel according to claim 1 , wherein the hydrogel is a self-supporting structure.

4. The hydrogel according to claim 1 , further comprising a pharmaceutically active agent.

5. The hydrogel according to claim 1 , wherein the self-aggregated tripeptide is present at a concentration of between 1-500 nM.

6. The hydrogel according to claim 1 , wherein the self-aggregated tripeptide is KYF.

7. The hydrogel according to claim 1 , wherein the self-aggregated tripeptide is KFF.

8. The hydrogel according to claim 1 , wherein the self-aggregated tripeptide is KYW.

9. The hydrogel according to claim 1 , wherein the self-aggregated tripeptide is KYY.

Assignments (3)
SECURITY INTEREST Recorded Jul 21, 2026
From: SEED HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A., AS LENDER
Reel/Frame 076028/0339 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2020
From: UNIVERSITY OF STRATHCLYDE
To: ENDO BIOLOGICS, INC.
Reel/Frame 051829/0017 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2017
From: ULIJN, REIN; TUTTLE, TELL; FREDERIX, PIM; SCOTT, GARY; ABUL-HAIJA, YOUSEF
To: UNIVERSITY OF STRATHCLYDE
Reel/Frame 043074/0071 →
Priority Claims (2)
GB 1417885.9 · Oct 9, 2014 · national
GB 1422993.4 · Dec 22, 2014 · national
Continuity (1)
Related Publication 20170246237A1 · Aug 31, 2017